염산미노사이클린
|
|
염산미노사이클린 속성
- 녹는점
- 205-210° (dec)
- 끓는 점
- 813℃
- 인화점
- >110°(230°F)
- 저장 조건
- 2-8°C
- 용해도
- 물에 조금 녹고, 에탄올에 약간 녹습니다(96%). 알칼리 수산화물과 탄산염 용액에 용해됩니다.
- 물리적 상태
- 수정 같은
- 색상
- 노란색
- 수용성
- 물에 자유롭게 용해됨
- Merck
- 14,6202
- 안정성
- 감광성
- InChIKey
- GLMUAFMGXXHGLU-VQAITOIOSA-N
- SMILES
- [C@@]12([H])C[C@@]3([H])C(C(=O)C4C(O)=CC=C(N(C)C)C=4C3)=C(O)[C@]1(O)C(=O)C(C(=O)N)=C(O)[C@H]2N(C)C.Cl |&1:0,3,21,31,r|
- LogP
- 0.808 (est)
- CAS 데이터베이스
- 13614-98-7(CAS DataBase Reference)
안전
- 위험 및 안전 성명
- 위험 및 사전주의 사항 (GHS)
위험품 표기 | Xi | ||
---|---|---|---|
위험 카페고리 넘버 | 36/37/38 | ||
안전지침서 | 26-36 | ||
유엔번호(UN No.) | 3249 | ||
WGK 독일 | 3 | ||
RTECS 번호 | QI7630500 | ||
위험 등급 | 6.1(b) | ||
포장분류 | III | ||
HS 번호 | 29413020 | ||
독성 | human,TDLo,oral,14286ug/kg/10 (14.286mg/kg),LUNGS, THORAX, OR RESPIRATION: RESPIRATORY OBSTRUCTIONLUNGS, THORAX, OR RESPIRATION: DYSPNEASKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE",Archives of Internal Medicine. Vol. 154, Pg. 1633, 1994. | ||
기존화학 물질 | KE-03048 |
염산미노사이클린 C화학적 특성, 용도, 생산
화학적 성질
Yellow Crystalline Powder용도
Minocycline hydrochloride is a salt prepared from minocycline, taking advantage of the two basic dimethylamino groups which protonate and readily form a salt from hydrochloric acid solutions. The hydrochloride is the preferred formulation for pharmaceutical applications. Like all tetracyclines, minocycline shows broad spectrum antibacterial and antiprotozoan activity and acts by binding to the 30S and 50S ribosomal sub-units, blocking protein synthesis.일반 설명
Minocycline, 7-dimethylamino-6-demethyl-6-deoxytetracycline(Minocin, Vectrin), the most potent tetracycline currentlyused in therapy, is obtained by reductive methylationof 7-nitro-6-demethyl-6-deoxytetracycline. It was releasedfor use in the United States in 1971. Because minocycline,like doxycycline, lacks the 6-hydroxyl group, it is stablein acids and does not dehydrate or rearrange to anhydroor lactone forms. Minocycline is well absorbed orally togive high plasma and tissue levels. It has a very long serumhalf-life, resulting from slow urinary excretion and moderateprotein binding. Doxycycline and minocycline, alongwith oxytetracycline, show the least in vitro calcium bindingof the clinically available tetracyclines. The improved distributionproperties of the 6-deoxytetracyclines have been attributedto greater lipid solubility.Perhaps the most outstanding property of minocyclineis its activity toward Gram-positive bacteria, especiallystaphylococci and streptococci. In fact, minocycline hasbeen effective against staphylococcal strains that are resistantto methicillin and all other tetracyclines, includingdoxycycline. Although it is doubtful that minocyclinewill replace bactericidal agents for the treatment of lifethreateningstaphylococcal infections, it may become auseful alternative for the treatment of less serious tissueinfections. Minocycline has been recommended for thetreatment of chronic bronchitis and other upper respiratorytract infections. Despite its relatively low renal clearance,partially compensated for by high serum and tissuelevels, it has been recommended for the treatment of urinary tract infections. It has been effective in the eradicationof N. meningitidis in asymptomatic carriers.
부작용
Common side effects of Minocycline hydrochloride include: nausea, vomiting, diarrhoea, dizziness, lightheadedness or spinning sensation. Individuals may experience symptoms of serious adverse reactions such as gingival hyperpigmentation, pain/difficulty swallowing, tinnitus or hearing loss, joint stiffness/pain/swelling, nephrotoxicity (elevated urea nitrogen, interstitial nephritis), hepatotoxicity (hyperbilirubinaemia, hepatic cholestasis, elevated liver enzymes, fatal hepatic failure, and jaundice), and hypersensitivity reactions. It rarely causes elevated pressure around the brain (intracranial hypertension - IH). The risk of this side effect is greater in women of childbearing age who are overweight or who have had IH in the past. Serious intestinal disorders including: non-stop diarrhoea, abdominal or stomach pain/cramps, and blood/mucus in the stool are less common.염산미노사이클린 준비 용품 및 원자재
원자재
준비 용품
염산미노사이클린 공급 업체
글로벌( 570)공급 업체
공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
---|---|---|---|---|---|
Biopole Pharmatech Co., Ltd. | +8615151475053 |
biopole@163.com | China | 37 | 58 |
Hebei Mojin Biotechnology Co., Ltd | +8613288715578 |
sales@hbmojin.com | China | 12456 | 58 |
Guangzhou Tengyue Chemical Co., Ltd. | +86-86-18148706580 +8618826483838 |
evan@tyvovo.com | China | 152 | 58 |
Sigma Audley | +86-18336680971 +86-18126314766 |
nova@sh-teruiop.com | China | 525 | 58 |
Shaanxi TNJONE Pharmaceutical Co., Ltd | +86-13474506593 +86-13474506593 |
sarah@tnjone.com | China | 874 | 58 |
Hebei Zhuanglai Chemical Trading Co.,Ltd | +8613343047651 |
admin@zlchemi.com | China | 401 | 58 |
Alpha Biopharmaceuticals Co., Ltd | +86-411-39042497 +8613921981412 |
sales@alphabiopharm.com | China | 886 | 58 |
Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 |
info@tianfuchem.com | China | 21691 | 55 |
Hangzhou FandaChem Co.,Ltd. | 008657128800458; +8615858145714 |
fandachem@gmail.com | China | 9348 | 55 |
Hubei XinRunde Chemical Co., Ltd. | +8615102730682 |
bruce@xrdchem.cn | CHINA | 566 | 55 |
염산미노사이클린 관련 검색:
페니실린 감마-일라디산염 세포 다이메틸아민 수화염화물 테트라사이클린 나프타센
2-PYRIMIDINAMINE, 4-(3,4-DIHYDRO-1-METHYL-2(1H)-ISOQUINOLINYL)-N-(4-FLUOROPHENYL)-5,6-DIMETHYL-, MONOHYDROCHLORIDE
Venlafaxine hydrochloride
NU1025
Minocycline Impurity 9
7-Didemethyl Minocycline Dihydrochloride (>85% by HPLC)
Starch
Tilmicosin phosphate
Ciprofloxacin hydrochloride
Erythromycin thiocyanate
Fisetin
Naringenin
Zoledronic acid
Veliparib
RG108